Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to deliver ~$24B in revenue in 2025. Comments taken from Q4 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- ABBV Earnings: AbbVie Rallies Alongside Q4 Beats
- Morning Movers: Apple and Exxon higher following quarterly earnings
- AbbVie reports Q4 adjusted EPS $2.16, consensus $2.26
- AbbVie sees FY25 adjusted EPS $12.12-$12.32, consensus $12.13
- AbbVie backs high single-digit compound annual revenue growth through 2029